Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966970 | 1.00 | SPHK2 (0.55) | SPHK2POLBL3MBTL1HPGDPDK2 | |
| SCHEMBL966968 | 1.00 | SPHK2 (0.55) | SPHK2POLBL3MBTL1HPGDPDK2 | |
| SCHEMBL970042 | 0.87 | HPGD (0.49) | SPHK2POLBL3MBTL1HPGDCHRNB2 | |
| SCHEMBL968549 | 0.87 | HPGD (0.49) | SPHK2POLBL3MBTL1HPGDCHRNB2 | |
| SCHEMBL968551 | 0.87 | HPGD (0.49) | SPHK2POLBL3MBTL1HPGDCHRNB2 | |
| SCHEMBL970043 | 0.87 | HPGD (0.49) | SPHK2POLBL3MBTL1HPGDCHRNB2 | |
| SCHEMBL10194843 | 0.85 | SPHK2 (0.55) | SPHK2POLBL3MBTL1HPGDPDK2 | |
| SCHEMBL17584872 | 0.85 | SPHK2 (0.55) | SPHK2POLBL3MBTL1HPGDPDK2 | |
| SCHEMBL4931440 | 0.84 | SPHK2 (0.64) | SPHK2POLBL3MBTL1PDK2ROCK2 | |
| SCHEMBL11447207 | 0.84 | SPHK2 (0.64) | SPHK2POLBL3MBTL1PDK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1970377-A1 | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | SPHK2 4285/4885POLB 2813/4885L3MBTL1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.